CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	3.51	37.31	371.21	1.2	914.96
Revenue Growth (YoY)	-90.59%	-89.95%	30885.48%	-99.87%	127154.94%
Cost of Revenue	498.29	430.9	517.58	571.9	441.75
Gross Profit	-494.78	-393.59	-146.38	-570.7	473.22
Selling, General & Admin	73.54	72.98	76.16	102.46	99.69
Operating Expenses	73.54	72.98	76.16	102.46	99.69
Operating Income	-568.32	-466.57	-222.54	-673.16	373.53
Interest & Investment Income	-	-	-	22.66	6
Other Non Operating Income (Expenses)	86.61	103.9	71.82	-	-
EBT Excluding Unusual Items	-481.71	-362.67	-150.72	-650.5	379.53
Pretax Income	-577.97	-362.67	-150.72	-650.5	379.53
Income Tax Expense	3.63	3.59	2.89	-0.33	1.87
Earnings From Continuing Operations	-581.6	-366.25	-153.61	-650.18	377.66
Net Income	-581.6	-366.25	-153.61	-650.18	377.66
Net Income to Common	-581.6	-366.25	-153.61	-650.18	377.66
Shares Outstanding (Basic)	90	84	79	78	76
Shares Outstanding (Diluted)	90	84	79	78	80
Shares Change (YoY)	6.60%	6.49%	1.90%	-3.29%	21.90%
EPS (Basic)	-6.47	-4.34	-1.94	-8.36	4.97
EPS (Diluted)	-6.47	-4.34	-1.94	-8.36	4.70
Free Cash Flow	-345.93	-144.68	-269.85	-532.93	457.27
Free Cash Flow Per Share	-3.85	-1.72	-3.41	-6.86	5.69
Gross Margin	-	-	-39.43%	-	51.72%
Operating Margin	-16191.40%	-1250.38%	-59.95%	-56190.40%	40.82%
Profit Margin	-16569.77%	-981.54%	-41.38%	-54271.70%	41.28%
Free Cash Flow Margin	-9855.50%	-387.72%	-72.69%	-44484.89%	49.98%
EBITDA	-548.84	-447.31	-202.7	-648.99	391.48
EBITDA Margin	-	-	-54.61%	-	42.79%
D&A For EBITDA	19.48	19.26	19.84	24.17	17.95
EBIT	-568.32	-466.57	-222.54	-673.16	373.53
EBIT Margin	-	-	-59.95%	-	40.82%
Effective Tax Rate	-	-	-	-	0.49%
Revenue as Reported	3.51	37.31	371.21	1.2	914.96

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q